IRF3 and neoplasm: CANA activated the STING/IRF3/IFN-β pathway in K7M2 tumor-bearing mice and osteosarcoma cells by impeding AKT phosphorylation levels (Wu et al., 2022), thereby synergistically inhibiting tumor growth when combined with 2′3′-cGAMP.